Observational studyBMC urology2026
Clinical predictors of symptom and quality-of-life improvement with antimuscarinics in overactive bladder: a 12-month prospective cohort study in Türkiye.
Observational study in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAntimuscarinic therapy is a first-line pharmacological treatment for overactive bladder (OAB), but individual response is highly variable. This study aimed to evaluate the effects of antimuscarinic therapy on symptom severity and quality of life (QoL) and to identify key clinical predictors of treatment response in a prospective cohort. MATERIALS AND
methodsA prospective observational cohort study was conducted at a gynecology outpatient clinic between August 2023 and August 2024. A total of 168 patients diagnosed with OAB who completed one year of antimuscarinic therapy (solifenacin, tolterodine, fesoterodine, or oxybutynin) were included. Disease-specific QoL was assessed using the Incontinence Quality of Life (I-QOL) questionnaire, and symptom severity was measured with the Incontinence Severity Index (ISI) at baseline and after three months. Multiple linear regression analysis was performed to identify independent predictors of changes in I-QOL and ISI scores.
resultsAntimuscarinic therapy led to significant improvements in both QoL and symptom severity. The mean total I-QOL score increased from 35.42 (± 13.32) to 61.18 (± 15.10) (p < 0.001), and the mean ISI score decreased from 10.68 (± 1.59) to 6.69 (± 1.70) (p < 0.001). However, regression analysis revealed that the therapeutic response was significantly moderated by specific factors. The experience of moderate to severe side effects, particularly dry mouth and constipation, was the strongest negative predictor of QoL improvement (β = -5.87, p = 0.001). Furthermore, increasing age (β = -0.028, p = 0.007), postmenopausal status (β = 0.585, p = 0.045), and the presence of metabolic comorbidities (diabetes/hypertension) were independently associated with diminished improvement in incontinence severity.
conclusionWhile effective, the benefit of antimuscarinic therapy in OAB is not uniform and is substantially limited by treatment-related side effects, advanced age, menopausal status, and metabolic comorbidities. These easily identifiable clinical factors should be used to personalize treatment selection, optimize patient counseling, and improve long-term management strategies, moving beyond a one-size-fits-all approach to OAB care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.